Perettie continues : “ We ’ re the only company that has end-to-end standalone research and development , manufacturing and commercialisation of a potentially curative treatment .”
Kite ’ s top priority is making sure that every patient who may benefit from CAR T has access to this therapy as early as possible to potentially save their life . This involves creating the right set of circumstances for patients to get access to this innovative treatment .
Every day matters for patients facing blood cancer , and Kite recognizes the critical importance of its supply chain and global manufacturing network to deliver these individualised therapies to patients .
This is where we invite Chris McDonald , Head of Technical Operations at Kite , to delve into the logistical side of the business , in particular how it delivers a highly individualised treatment to the masses in a seamless way while also addressing the impact of its supply chain on the environment and its stakeholders .
“ We made some decisions early on – commitments to really build out our capacity and our manufacturing and supply chain teams as well as quality assurance teams ,” says McDonald . “ Those decisions allow us not only to have really good turnaround times and success rates , but we also have the additional capacity so that a patient has a manufacturing slot .” This approach to the manufacturing portion of treatment delivery is driven by the mindset of continuous improvement
healthcare-digital . com 83